Addition of atezolizumab to nab-paclitaxel plus carboplatin is a new standard option for the first-line treatment for non-squamous non-small cell lung cancer

被引：1
|
作者：
Yamaguchi, Teppei [1 ]
Hida, Toyoaki [1 ]
机构：
[1] Aichi Canc Ctr Hosp, Dept Thorac Oncol, Nagoya, Aichi, Japan
来源：
TRANSLATIONAL CANCER RESEARCH | 2019年 / 8卷 / 08期
关键词：
PHASE-III; MAINTENANCE BEVACIZUMAB; CHEMOTHERAPY; COMBINATION; NIVOLUMAB; DOCETAXEL; EFFICACY; THERAPY; SAFETY;
D O I：
10.21037/tcr.2019.12.57
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E11 / E14
页数：4
相关论文
共 50 条
  • [1] Bevacizumab Plus Carboplatin Plus Nab-paclitaxel for Non-squamous Non-small Cell Lung Cancer in a Real-world Setting
    Tamiya, Akihiro
    Tamiya, Motohiro
    Inagaki, Yuji
    Taniguchi, Yoshihiko
    Nakao, Keiko
    Matsuda, Yoshinobu
    Kawamura, Takahisa
    Kunimasa, Kei
    Inoue, Takako
    Nishino, Kazumi
    Okishio, Kyoichi
    [J]. ANTICANCER RESEARCH, 2023, 43 (03) : 1325 - 1330
  • [2] Atezolizumab plus carboplatin and nab-paclitaxel versus carboplatin and nab-paclitaxel as treatments for Chinese, treatment-naive, stage IV, non-squamous, non-small-cell lung cancer patients: A retrospective analysis
    Chen, Yingkai
    Kang, Shizhou
    Yan, Ming
    [J]. PHARMACOLOGY RESEARCH & PERSPECTIVES, 2022, 10 (03):
  • [3] Phase 2 study of bevacizumab plus carboplatin/nab-paclitaxel followed by bevacizumab plus nab-paclitaxel for non-squamous non-small cell lung cancer with malignant pleural effusion
    Tamiya, Motohiro
    Tamiya, Akihiro
    Suzuki, Hidekazu
    Taniguchi, Yoshihiko
    Katayama, Kanako
    Minomo, Shojiro
    Nakao, Keiko
    Takeuchi, Naoko
    Matsuda, Yoshinobu
    Naito, Yujiro
    Shiroyama, Takayuki
    Okamoto, Norio
    Okishio, Kyoichi
    Kumagai, Toru
    Atagi, Shinji
    Imamura, Fumio
    Hirashima, Tomonori
    [J]. INVESTIGATIONAL NEW DRUGS, 2021, 39 (04) : 1106 - 1112
  • [4] First-line nab-paclitaxel plus carboplatin for patients with advanced non-small cell lung cancer: Results of the NEPTUN study
    Dechow, Tobias
    Riera-Knorrenschild, Jorge
    Hackanson, Bjoern
    Janssen, Jan
    Schulz, Holger
    Chiabudini, Marco
    Fischer von Weikersthal, Ludwig
    Budweiser, Stephan
    Nacke, Axel
    Taeuscher, Dagmar
    Welslau, Manfred
    Potthoff, Karin
    [J]. CANCER MEDICINE, 2021, 10 (22): : 8127 - 8137
  • [5] Real-world Efficacy and Safety of Atezolizumab Plus Bevacizumab, Paclitaxel and Carboplatin for First-line Treatment of Japanese Patients With Metastatic Non-squamous Non-small Cell Lung Cancer
    Ikeuchi, Nobumitsu
    Igata, Fumiyasu
    Kinoshita, Eriko
    Kawabata, Toshiaki
    Tan, Ibun
    Osaki, Yusuke
    Otsuka, Rikako
    On, Rintaro
    Ikeda, Takato
    Nakao, Akira
    Sasaki, Tomoya
    Aoyama, Takashi
    Hirano, Ryosuke
    Harada, Taishi
    Ebi, Noriyuki
    Fujita, Masaki
    Inoue, Hiroyuki
    [J]. ANTICANCER RESEARCH, 2023, 43 (02) : 713 - 724
  • [6] A phase II study of nab-paclitaxel and carboplatin chemotherapy plus necitumumab in the first-line treatment of patients with stage IV squamous non-small cell lung cancer
    Villaruz, Liza C.
    Cobo, Manuel
    Syrigos, Konstantinos
    Mavroudis, Dimitrios
    Zhang, Wei
    Kim, Jong Seok
    Socinski, Mark A.
    [J]. LUNG CANCER, 2019, 136 : 52 - 56
  • [7] First-line nab-paclitaxel plus carboplatin for patients with advanced non-small cell lung cancer: Final results of the NEPTUN study
    Dechow, Tobias
    Riera-Knorrenschild, Jorge
    Hackanson, Bjorn
    Janssen, Jan
    Schulz, Holger
    Oppermann, Ursula
    Chiabudini, Marco
    von Weikersthal, Ludwig Fischer
    Budweiser, Stephan
    Nacke, Axel
    Taeuscher, Dagmar
    Welslau, Manfred
    Potthoff, Karin
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2023, 153 (01) : 141 - 152
  • [8] Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutations
    Reck, Martin
    Shankar, Geetha
    Lee, Anthony
    Coleman, Shelley
    McCleland, Mark
    Papadimitrakopoulou, Vassiliki A.
    Socinski, Mark A.
    Sandler, Alan
    [J]. EXPERT REVIEW OF RESPIRATORY MEDICINE, 2020, 14 (02) : 125 - 136
  • [9] Carboplatin plus Weekly Paclitaxel with Bevacizumab for First-line Treatment of Non-small Cell Lung Cancer
    Kubota, Tetsuya
    Okano, Yoshio
    Sakai, Mizu
    Takaoka, Masato
    Tsukuda, Tsukie
    Anabuki, Kazuki
    Kawase, Shigeo
    Miyamoto, Shintaro
    Ohnishi, Hiroshi
    Hatakeyama, Nobuo
    Machida, Hisanori
    Urata, Tomoyuki
    Yamamoto, Akira
    Ogushi, Fumitaka
    Yokoyama, Akihito
    [J]. ANTICANCER RESEARCH, 2016, 36 (01) : 307 - 312
  • [10] Cost-Effectiveness Analysis of Atezolizumab Plus Chemotherapy in the First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer
    Ding, Dong
    Hu, Huabin
    Liao, Mengting
    Shi, Yin
    She, Longjiang
    Yao, Linli
    Zhu, Youwen
    Zeng, Shan
    Huang, Jin
    [J]. ADVANCES IN THERAPY, 2020, 37 (05) : 2116 - 2126
12345